Frazier Life Sciences Adds Experienced Biopharmaceutical Executive to Team
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"I have known Jan for many years and am very excited to have him join Frazier," said Managing Partner Albert Cha. "He is a highly experienced biopharmaceutical executive, and we look forward to working with him to identify and evaluate attractive life sciences investment opportunities."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
MENLO PARK, Calif. -- Businesswire -- Frazier Life Sciences announced the addition of Jan Møller Mikkelsen as a Senior Advisor. He has over 30 years of experience as a biopharmaceutical executive.
Mr. Mikkelsen founded Ascendis Pharma (NASDAQ: ASND) and currently serves as full-time President and Chief Executive Officer, as well as a board member. He previously served as President and Chief Executive Officer of LifeCycle Pharma A/S (acquired by Asahi Kasei Pharma), as well as President of the Pharmaceutical Division of Maxygen, Inc. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S (acquired by Maxygen, Inc.), where he served as Co-Chief Executive Officer. He has also held various positions at Novo Nordisk A/S, including Vice President of Protein Discovery. In addition, Mr. Mikkelsen serves as Chairman of the board of directors for Hummingbird Bioscience.
Mr. Mikkelsen received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark, and pursued his post-doctoral research at Children’s Hospital in Oakland, CA.
“I have known Jan for many years and am very excited to have him join Frazier,” said Managing Partner Albert Cha. “He is a highly experienced biopharmaceutical executive, and we look forward to working with him to identify and evaluate attractive life sciences investment opportunities.”
About Frazier Life Sciences
Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise over $3.3 billion in capital raised, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, 62 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London.
For more information about Frazier Life Sciences, please visit www.frazierls.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005286/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Frazier Life Sciences
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 동구바이오제약, 세계 최초 조루 복합제 ‘구세정’ 출시 예정 - 뉴스와이어
- 압타머사이언스, 혈액 기반 폐암진단키트 인도시장 진출 위한 MOU 체결 - 뉴스와이어
- 아로마티카, 국내 뷰티 브랜드 최초 SBTi 승인 획득 - 뉴스와이어
- 투썸플레이스, 비비와 함께한 ‘아박’ 광고 조회수 1000만 뷰 돌파 - 뉴스와이어
- LIG넥스원, 합동군사대와 ‘미래 국방 군사전문가 육성 MOU’ 체결 - 뉴스와이어
- 동원산업, 30g씩 소포장해 편의성 높인 ‘짜먹는 간편 명란’ 출시 - 뉴스와이어
- RWS 코리아, 최첨단 AI 탑재 번역툴 ‘트라도스 스튜디오 2024’ 출시 - 뉴스와이어
- 비즈니스북스 ‘어떻게 팔지 막막할 때 읽는 카피 책’ 출간 - 뉴스와이어
- 스프린트 프로그램, IIMSTC와 인도 합작 법인 출범 - 뉴스와이어
- 돌비 시네마, 여름 극장가 흥행 정조준하는 6월 개봉작 소개 - 뉴스와이어